BibTex format
@article{Scachetti:2025:10.1016/S1473-3099(24)00619-4,
author = {Scachetti, GC and Forato, J and Claro, IM and Hua, X and Salgado, BB and Vieira, A and Simeoni, CL and Barbosa, ARC and Rosa, IL and de, Souza GF and Fernandes, LCN and de, Sena ACH and Oliveira, SC and Singh, CML and de, Lima STS and de, Jesus R and Costa, MA and Kato, RB and Rocha, JF and Santos, LC and Rodrigues, JT and Cunha, MP and Sabino, EC and Faria, NR and Weaver, SC and Romano, CM and Lalwani, P and Proenca-Modena, JL and de, Souza WM},
doi = {10.1016/S1473-3099(24)00619-4},
journal = {Lancet Infect Dis},
pages = {166--175},
title = {Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study.},
url = {http://dx.doi.org/10.1016/S1473-3099(24)00619-4},
volume = {25},
year = {2025}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BACKGROUND: Oropouche virus is an arthropod-borne virus that has caused outbreaks of Oropouche fever in central and South America since the 1950s. This study investigates virological factors contributing to the re-emergence of Oropouche fever in Brazil between 2023 and 2024. METHODS: In this observational epidemiological study, we combined multiple data sources for Oropouche virus infections in Brazil and conducted in-vitro and in-vivo characterisation. We collected serum samples obtained in Manaus City, Amazonas state, Brazil, from patients with acute febrile illnesses aged 18 years or older who tested negative for malaria and samples from people with previous Oropouche virus infection from Coari municipality, Amazonas state, Brazil. Basic clinical and demographic data were collected from the Brazilian Laboratory Environment Management System. We calculated the incidence of Oropouche fever cases with data from the Brazilian Ministry of Health and the 2022 Brazilian population census and conducted age-sex analyses. We used reverse transcription quantitative PCR to test for Oropouche virus RNA in samples and subsequently performed sequencing and phylogenetic analysis of viral isolates. We compared the phenotype of the 2023-24 epidemic isolate (AM0088) with the historical prototype strain BeAn19991 through assessment of titre, plaque number, and plaque size. We used a plaque reduction neutralisation test (PRNT50) to assess the susceptibility of the novel isolate and BeAn19991 isolate to antibody neutralisation, both in serum samples from people previously infected with Oropouche virus and in blood collected from mice that were inoculated with either of the strains. FINDINGS: 8639 (81·8%) of 10 557 laboratory-confirmed Oropouche fever cases from Jan 4, 2015, to Aug 10, 2024, occurred in 2024, which is 58·8 times the annual median of 147 cases (IQR 73-325). Oropouche virus infections were reported in all 27 federal units, with 8182 (77·5%) of
AU - Scachetti,GC
AU - Forato,J
AU - Claro,IM
AU - Hua,X
AU - Salgado,BB
AU - Vieira,A
AU - Simeoni,CL
AU - Barbosa,ARC
AU - Rosa,IL
AU - de,Souza GF
AU - Fernandes,LCN
AU - de,Sena ACH
AU - Oliveira,SC
AU - Singh,CML
AU - de,Lima STS
AU - de,Jesus R
AU - Costa,MA
AU - Kato,RB
AU - Rocha,JF
AU - Santos,LC
AU - Rodrigues,JT
AU - Cunha,MP
AU - Sabino,EC
AU - Faria,NR
AU - Weaver,SC
AU - Romano,CM
AU - Lalwani,P
AU - Proenca-Modena,JL
AU - de,Souza WM
DO - 10.1016/S1473-3099(24)00619-4
EP - 175
PY - 2025///
SP - 166
TI - Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study.
T2 - Lancet Infect Dis
UR - http://dx.doi.org/10.1016/S1473-3099(24)00619-4
UR - https://www.ncbi.nlm.nih.gov/pubmed/39423838
VL - 25
ER -